Enterococcal bacteraemia: Factors influencing mortality, length of stay and costs of hospitalization

Clinical Microbiology and Infection

Volumn 19, Issue 4, 2013, Pages

  Cheah, A L Y ^a,b,c   Spelman, T ^a,d   Liew, D ^e   Peel, T ^f   Howden, B P ^c,f   Spelman, D ^a,b,g   Grayson, M L ^c,f   Nation, R L ^a   Kong, D C M ^a  

^a MONASH UNIVERSITY   (Australia)

^b The Alfred ^*  (Australia)

^c AUSTIN HEALTH   (Australia)

^d BURNET INSTITUTE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g Microbiology Unit   (Australia)

Author keywords

Bacteraemia; Cost; Enterococci; Health outcomes; Length of stay; Mortality

Indexed keywords

AMPICILLIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TIMENTIN; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; BACTEREMIA; COMORBIDITY; ECONOMIC ASPECT; ENTEROCOCCAL INFECTION; FEMALE; HOSPITALIZATION COST; HUMAN; INFORMATION PROCESSING; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNIVARIATE ANALYSIS; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS;

ENTEROCOCCUS;

EID: 84875530494     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12132     Document Type: Article

References (30)

1. Hidron Alicia I, Edwards Jonathan R, Patel J et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29: 996-1011.
2. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000; 13: 686-707.
3. Bell J, Turnidge J, Coombs G, O'Brien F. Emergence and epidemiology of vancomycin-resistant enterococci in Australia. Commun Dis Intell 1998; 22: 249-252.
4. Butler AM, Olsen Margaret A, Merz Liana R et al. Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort. Infect Control Hosp Epidemiol 2011; 31: 28-35.
5. Song X, Srinivasan A, Plaut D, Perl T. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 2003; 24: 251-256.
6. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128-140.
7. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the united states. J Am Med Assoc 2007; 298: 1763-1771.
8. Klevens RM, Morrison MA, Fridkin SK et al. Community-associated methicillin-resistant Staphylococcus aureus and healthcare risk factors. Emerg Infect Dis 2006; 12: 1991-1993.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
10. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999; 11: 7-12.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
12. Durkalski VL, Palesch YY, Lipsitz SR, Rust PF. Analysis of clustered matched-pair data. Stat Med 2003; 22: 2417-2428.
13. Powell JL. Least absolute deviations estimation for the censored regression model. J Econometrics 1984; 25: 303-325.
14. Pregibon D. Goodness of link tests for generalized linear models. J Roy Stat Soc C Appl Stat 1980; 29: 15-14.
15. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005; 41: 327-333.
16. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med 2001; 135: 484-492.
17. Camins BC, Farley MM, Jernigan JJ, Ray SM, Steinberg JP, Blumberg HM. A population-based investigation of invasive vancomycin-resistant enterococcus infection in metropolitan atlanta, georgia, and predictors of mortality. Infect Control Hosp Epidemiol 2007; 28: 983-991.
18. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998; 158: 522-527.
19. Vydra J, Shanley RM, George I et al. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55: 764-770.
20. Han SH, Chin BS, Lee HS et al. Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome. J Infect 2009; 58: 182-190.
21. Erlandson K, Sun J, Iwen P, Rupp M. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. Clin Infect Dis 2008; 46: 30-36.
22. McKinnell JA, Patel M, Shirley RM, Kunz DF, Moser SA, Baddley JW. Observational study of the epidemiology and outcomes of vancomycin-resistant enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol Infect 2011; 139: 1342-1350.
23. Crank CW, Scheetz MH, Brielmaier B et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin Ther 2010; 32: 1713-1719.
24. Mave V, Garcia-Diaz J, Islam T, Hasbun R. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother 2009; 64: 175-180.
25. Twilla JD, Finch CK, Usery JB, Gelfand MS, Hudson JQ, Broyles JE. Vancomycin-resistant enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin. J Hosp Med 2012; 7: 243-248.
26. Suppli M, Aabenhus R, Harboe ZB, Andersen LP, Tvede M, Jensen JU. Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. Clin Microbiol Infect 2011; 17: 1078-1083.
27. Shay DK, Maloney SA, Montecalvo M et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172: 993-1000.
28. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998; 26: 1127-1133.
29. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20: 318-323.
30. Hamel MB, Phillips RS, Teno JM et al. Seriously ill hospitalized adults: do we spend less on older patients? J Am Geriatr Soc 1996; 44: 1043-1048.